Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Google 2009 PageRank: #2 Among Top Health News and Media Publications
Google 2009 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2009 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2009 PageRank: #2 News and Media Site for the Pharmaceutical Industry
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
2009 SEP 14 ... - hormone replacement therapy for the treatment of menopause; A birth control patch; buprenorphine Transtec™, Norspan™, Butrans™ patches for the treatment of chronic ...
2009 OCT 19 ... who are tolerant to opioid therapy for their underlying persistent cancer pain, and BEMA Buprenorphine, an analgesic in Phase 2 clinical development with at least one potential target ...
2009 OCT 19 ... who are tolerant to opioid therapy for their underlying persistent cancer pain, and BEMA Buprenorphine, an analgesic in Phase 2 clinical development with at least one potential target ...
2009 OCT 19 ... who are tolerant to opioid therapy for their underlying persistent cancer pain, and BEMA Buprenorphine, an analgesic in Phase 2 clinical development with at least one potential target ...
2009 SEP 14 ... who are tolerant to opioid therapy for their underlying persistent cancer pain, and BEMA Buprenorphine, a an analgesic in Phase 2 clinical development with at least one potential target ...
2009 OCT 5 ... buccal soluble film) and the status of BDSI's product pipeline, including BEMA Buprenorphine and other potential future product opportunities utilizing the BEMA drug delivery ...
2009 NOV 23 ... predictors of long-term virological success. At baseline, 53 patients were receiving buprenorphine, 28 patients were receiving methadone, and 32 patients were not on OST. The median ...
2009 NOV 16 ... in Berlin, Germany report. "In fact, morphine, hydromorphone, fentanyl and buprenorphine increased the number of migrated HaCaT cells (spontaneously transformed keratino-cytes) ...
2009 NOV 16 ... is well documented. Transdermal delivery systems (TDS) containing fentanyl or buprenorphine could potentiality have advantages over oral and parenteral routes, but evidence from ...
2009 OCT 27 ... to a study from Singapore, Singapore, "Drug users who crush, dissolve, and inject buprenorphine tablets parenterally may be at risk of severe thromboembolic complications or death. We ...
2009 NOV 9 ... According to recent research from Cambridge, the United Kingdom, "The 7-day, low-dose buprenorphine patch has been available in the United Kingdom since 2005 for the treatment of chronic ...
2009 SEP 28 ... were restricted to the femoral (86.7%) and brachial (13.3%) areas. The drug involved was buprenorphine (Subutex) in all cases. Pain over the limb swelling (100%), pulsatility (60%), and ...
2009 SEP 22 ... activity were measured. Repeated administration of the mu agonists, morphine and buprenorphine, produced a progressive increase in locomotor activity during the treatment period, and ...
Subject: Pharmacology and Experimental Therapeutics
2009 NOV 2 ... (ii) summarizes the pharmacology of perineural adjuvants (epinephrine, clonidine, buprenorphine, midazolam, tramadol, and dexamethasone), and (iii) identifies areas that warrant ...
2009 NOV 2 ... was reported in comparison with systemic controls in most of the studies, except buprenorphine. Also clonidine is controversial as an analgesic adjuvant. Special factors, such as type ...
2009 OCT 12 ... new data in the report 'Treatment of opioid-dependent adolescents and young adults with buprenorphine.' According to recent research from the United States, "Rising rates of opioid use ...
2009 SEP 21 ... the locomotor effects of cocaine were tested 8 days later. The mu agonists, morphine and buprenorphine, and the delta agonist, BW373U86 [(+/-)-4-[(R*)[(2S*, ...
2009 SEP 14 ... "The most commonly used detoxification agents in UK prisons are currently buprenorphine and methadone, both are recommended by national clinical guidelines. However, these ...
2009 OCT 5 ... Australia conducted a study "To examine the levels and predictors of injection of buprenorphine-naloxone (BNX) - a combination of a partial opioid agonist and an opioid antagonist for ...
2009 SEP 21 ... of all federal and state prison systems offer ORT with the medications methadone and buprenorphine, and only in very limited circumstances. Similarly, only twenty-three states provide ...
